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Abstract
Background: An accurate forecast of global demand is essential to stabilize the market for
artemisinin-based combination therapy (ACT) and to ensure access to high-quality, life-saving
medications at the lowest sustainable prices by avoiding underproduction and excessive
overproduction, each of which can have negative consequences for the availability of affordable
drugs. A robust forecast requires an understanding of the resources available to support
procurement of these relatively expensive antimalarials, in particular from the Global Fund, at
present the single largest source of ACT funding.
Methods: Predictive regression models estimating the timing and rate of disbursements from the
Global Fund to recipient countries for each malaria grant were derived using a repeated split-
sample procedure intended to avoid over-fitting. Predictions were compared against actual
disbursements in a group of validation grants, and forecasts of ACT procurement extrapolated
from disbursement predictions were evaluated against actual procurement in two sub-Saharan
countries.
Results: Quarterly forecasts were correlated highly with actual smoothed disbursement rates (r
= 0.987, p < 0.0001). Additionally, predicted ACT procurement, extrapolated from forecasted
disbursements, was correlated strongly with actual ACT procurement supported by two grants
from the Global Fund's first (r = 0.945, p < 0.0001) and fourth (r = 0.938, p < 0.0001) funding
rounds.
Conclusion:  This analysis derived predictive regression models that successfully forecasted
disbursement patterning for individual Global Fund malaria grants. These results indicate the utility
of this approach for demand forecasting of ACT and, potentially, for other commodities procured
using funding from the Global Fund. Further validation using data from other countries in different
regions and environments will be necessary to confirm its generalizability.
Published: 2 October 2008
Malaria Journal 2008, 7:200 doi:10.1186/1475-2875-7-200
Received: 12 June 2008
Accepted: 2 October 2008
This article is available from: http://www.malariajournal.com/content/7/1/200
© 2008 Cohen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2008, 7:200 http://www.malariajournal.com/content/7/1/200
Page 2 of 9
(page number not for citation purposes)
Background
Since the 1970s, the rise of global resistance to the cheap,
ubiquitous antimalarial chloroquine (CQ) has made it
imperative to find new, effective drugs to fight Plasmodium
falciparum, the parasite species responsible for a majority
of malaria-related mortality worldwide. Modern artemisi-
nin drugs were first developed by the Chinese for the Viet
Cong during the Vietnam-American War, on the basis of
ancient Chinese fever remedies involving Artemisia annua,
the sweet wormwood plant. Artemisinin-based combina-
tion therapy (ACT), which utilizes artemisinin along with
an additional partner drug, such as amodiaquine, lume-
fantrine or mefloquine, is now widely considered the
most effective treatment for uncomplicated malaria [1].
Following a 2003 critique in the Lancet [2], the WHO
revised its malaria treatment guidelines to recommend
ACT over all other therapies [1], and the Global Fund to
Fight AIDS, Tuberculosis and Malaria ("the Global Fund")
began to support acceleration of ACT scale-up actively [3].
The ensuing sudden upsurge in demand for artemisinin
caused large fluctuations in the price and supply of artem-
isinin. An initially inadequate supply of this key ingredi-
ent resulted in a sharp price increase up to $1,200 per kg
in 2004–2005, but prices then plunged to as low as $170
per kg in 2007 following subsequent overproduction [4].
Accurate forecasts are needed to stabilize the market by
ensuring that production reflects demand [5], but such
efforts are complicated by the uncertainty and opacity of
global procurement operations. The assessment of the
forecasting landscape by a 2004 Institute of Medicine
report was bleak: "There is widespread agreement that accu-
rate forecasts of demand are essential to the success of procure-
ment operations. Agreement is equally widespread that
accurately forecasting the demand for antimalarials is nearly
impossible"[6].
The environment surrounding forecasting today remains
dynamic, with evolution of national treatment guidelines
[7] and continued deployment of new ACT products [8].
The potential implementation of a global subsidy under
the Roll Back Malaria (RBM) Affordable Medicines Facil-
ity for Malaria has further complicated efforts, since such
a subsidy has the potential to cause substantial increases
in demand for ACT, through a dramatic reduction of the
price of these products [6]. For forecasting efforts to main-
tain credibility under such dynamic circumstances, they
must be adaptable and robust, with explicit and transpar-
ent specification of underlying assumptions, source data,
and methodology.
Accurate forecasting of demand is critical for ACT, because
the key ingredient, artemisinin, is a natural product
derived from a plant, creating supply chain challenges [9].
Production of an ACT requires 12 to 24 months from the
planting of Artemisia annua to ACT production [4]. This
timeline compares to three to five months for either fully
synthetic drugs (e.g., antiretrovirals or tuberculosis drugs)
or semi-synthetic drugs requiring fermentation processes
(e.g., some antibiotics). Given the lengthy lead time
required, accurate forecasting of procurement is critical to
ensure access to high-quality, life-saving ACTs at the low-
est sustainable prices [6] by avoiding the twin dangers of
underproduction – which would lead to shortages and
higher prices – and excessive overproduction – which
would lead to expiry of these drugs, which have a shelf-life
of about two years [8], and losses for suppliers that might
drive some out of the market and reduce incentives for
others to enter it.
ACT is significantly more expensive than conventional
antimalarial medicines [8], necessitating support from
donor organizations for purchase by resource-limited
governments. Because of the importance of this funding,
accurate forecasting of ACT procurement requires under-
standing the dynamics of the donor funding mechanisms.
The Global Fund is presently the single largest funding
source for ACT procurement worldwide, funding an esti-
mated 264 million treatments through its fifth funding
round [10]. Analysis of global ACT financing indicates
that the Global Fund is responsible for funding approxi-
mately 70–78% of all public sector ACT procurement
[11]. Funding of ACT through non-Global Fund mecha-
nisms by other actors, including the United States Presi-
dent's Malaria Initiative, UNITAID, and the World Bank,
while significant, comprises a much smaller share of glo-
bal volumes. Given that the Global Fund drivers a major-
ity of the world's ACT volumes, careful understanding and
robust prediction of its funding process will comprise an
essential component of an accurate global demand fore-
cast.
During each round, countries apply to the Global Fund
for funding by submitting a proposal. Funding for
approved proposals is transmitted to recipient countries
through a series of disbursements. The magnitude and
timing of each disbursement of funding is contingent
upon the country's performance in meeting key mile-
stones (e.g., distribution of procured ACT) as stated in the
approved grant agreement, as well as the country's com-
pliance with the Global Fund's policies. Disbursement of
awarded funding may slow or be halted if a country's
progress is deemed insufficient. Thus, it is hypothesized
that the rate at which a grant is disbursed can be consid-
ered an indicator of grant progress. For example, if a sub-
stantial portion of a particular grant is intended for ACT
procurement, a large disbursement rate may be consid-
ered indicative of successful procurement (although per-
formance of all grant components is taken into
consideration when determining grant disbursements),Malaria Journal 2008, 7:200 http://www.malariajournal.com/content/7/1/200
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and the magnitude and timing of that procurement can be
estimated as a function of the supporting grant's disburse-
ment rate.
Past research has investigated factors associated with grant
performance. Lu et al [12] used random effects analyses to
look for associations between characteristics of grants and
recipients and quarterly disbursement of funds. They
found that large grants had lower disbursement rates and
grants with private principal recipients were disbursed
more rapidly. Additionally, higher political stability indi-
ces, lower gross domestic product (GDP), and lower pro-
portion of GDP spent on health all were associated with
faster rates of disbursement. Radelet and Siddiqi [13]
identified characteristics of the grant and recipient that
were associated with evaluation scores (higher scores will
be correlated with greater disbursement rates). The inves-
tigation found that poorly rated grants were more likely to
have governmental principal recipients, be focused on
malaria, have weak initial proposals, or be evaluated by
particular firms, while having more doctors, higher mea-
sles immunization rate, few other donors, and high dis-
ease prevalence were associated with higher scores.
The analysis presented here describes the derivation of
predictive regression models to forecast the rate at which
malaria grant funding is disbursed from the Global Fund
to recipient countries. The utility of these predictions for
estimation of future ACT procurement then is demon-
strated using importation records from two sub-Saharan
African countries.
Methods
Data on Global Fund grant awards [14] and disburse-
ments [15] were downloaded from the Global Fund web-
site for analysis. Historical disbursement of each Global
Fund malaria grant awarded in funding Rounds 1–6 was
represented by a simple linear regression line, fit using the
date as the predictor variable and the daily cumulative dis-
bursement amount (beginning the day the grant was
approved and ending on either the date of grant comple-
tion or 1 January, 2008, whichever came first) as the out-
come. From this line, two key parameters were defined
(Figure 1):
(1) The rate at which funding was disbursed from the Glo-
bal Fund to the recipient country (the disbursement
slope)
(2) The date on which disbursement began (the disburse-
ment line intercept)
Model fitting
Predictive regression models may include variables that
are not statistically significant and exclude others that are,
since statistical association does not necessarily indicate
useful predictive value [16]. To prevent over-fitting of
models to the training dataset and to ensure that the vari-
ables included in models were not merely statistically sig-
nificant but also demonstrated predictive ability [17,18],
models were constructed using a repeated split-sample
procedure (Figure 2). Only those grants for which the Glo-
bal Fund had made at least three prior funding disburse-
ments to the recipient country (n = 130) were used to fit
and test the predictive models, since initial disbursements
might not be indicative of future performance. A ran-
domly selected 75% (n = 97) of these Round 1–6 grants
Fitting disbursement slopes and intercepts Figure 1
Fitting disbursement slopes and intercepts. Depiction 
of the ordinary least-squares regression used to calculate the 
disbursement slope and intercept for a hypothetical Global 
Fund grant.
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Diagram of split-sample model fitting methodology.
130 grants with > 3 disbursements
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(n=97)
Validation group 
(n=33)
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In Fit Set, fit regression models predicting 
slopes & intercepts using all possible sets 
of candidate predictor variables
Use models to predict slopes & intercepts in 
Validation Set
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Fit final model for all of Derivation group 
and use to predict Validation group
Model fitting (99 times)
Select predictors with best average fit
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were used to fit and compare models constructed with
candidate variables (the "derivation group"), while the
remaining 25% of grants (n = 33) were set aside during
model fitting to permit validation on data not used to fit
the model (the "validation group").
Two models were constructed, one to predict the disburse-
ment slope, and the other to predict the intercept of the
disbursement line. Variable selection for each model
occurred through a series of 99 model fitting and testing
repetitions (Figure 2). In each iteration, the 97 grants in
the derivation group were subdivided into further random
sets: 75% were assigned to a fitting set and 25% to a test-
ing set. The fitting set was used to construct models
involving different combinations of candidate variables;
candidate predictor variables are listed in Table 1. These
models then were compared according to their ability to
predict the slope or intercept of the fit disbursement lines
in the testing set. The best predicting set of variables was
judged according to which produced the lowest root-
mean-square error (RMSE) for each repetition. The sets of
variables that produced the lowest average RMSE over all
99 repetitions were selected to construct final models.
After variable selection, final models predicting slope and
intercept were fit using all 97 grants in the derivation
group. These multivariate regression models then were
used to predict the disbursement slopes and intercepts for
the unused 33 grants in the validation dataset. Each
grant's predicted slope and intercept were used to generate
a line representing estimated funding disbursements,
extending until either reaching the grant's maximum
potential or expiration date, whichever came first. The
expiration date was calculated by adding the planned
length of the grant to the grant start date. Predicted quar-
terly disbursements for 2003–2007 were summed across
all grants, and these predictions were compared against
summations of the actual disbursement lines fit to grant
disbursement history [15] as well as the summation of
planned funding from grant proposals [19].
Summation of planned funding for malaria grants
To examine how actual grant performance differed from
planned disbursement, the amount of funding requested
by recipient countries from the Global Fund for each year
of the grant was extracted from the 146 approved malaria
grant proposals listed on the Global Fund website [19].
Since total proposed funding may not match the actual
amounts subsequently awarded in all cases, each year's
requested funding was normalized against the actual
awarded total [14]. The starting date for each grant was
used to mark the beginning of that grant's first year, and
the expected quarterly funding for each successive year
(up to five) thereafter was extracted. Total expected dis-
bursements for each quarter were then calculated by sum-
ming expected funding for each grant, and these totals
were compared against the actual disbursement rates as
well as those forecasted by the predictive models.
Estimating ACT procurement using forecasted 
disbursement
Each approved malaria Global Fund proposal was read to
determine the proportion of each year's request intended
for procurement of drugs for uncomplicated malaria. The
percentage of the grant intended for procurement of drugs
for uncomplicated malaria was then calculated separately
for Phase 1 (years 1–2) and Phase 2 (years 3–5) of the
grant, if applicable. If an itemized drug budget was not
available in a particular proposal (39 proposals), average
values were substituted from either the applicant coun-
try's other grant proposals, when possible, or otherwise
from all grants in that funding round.
Multiplying predicted disbursements by the percentage
intended for procurement of drugs for uncomplicated
malaria resulted in a prediction of the amount of funding
Table 1: Candidate explanatory variables entered into predictive regression models
Grant characteristics Country characteristics
Funding round Number of previous malaria grants
Grant amount per populace Number of previous grants of any type
Phase 1 and 2 potential grant amount Population
Phase 1 and 2 agreed grant amount World region
Principal Recipient (PR) type Control of Corruption Index [24]
Local Fund Agent (LFA) Political Stability Index [24]
Planned grant length Government Effectiveness Index [24]
Physicians per populace [25]
Measles immunization rate for < 1 yr olds [25]
Observer Human Rights Index [26]
Estimated malaria cases [27]
Under-five mortality rate [28]
GDP per capita [29]Malaria Journal 2008, 7:200 http://www.malariajournal.com/content/7/1/200
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available for ACT procurement for each grant. Because
ACT orders are customarily delivered to countries in stag-
gered shipments over the course of a year, forecasted
demand for ACT was lagged one year behind predicted
disbursements from the Global Fund to recipient coun-
tries. For example, hypothetical country × might receive a
disbursement of $1 M on 1 Jan 2005; of this $1 M, the
Global Fund grant calls for 80% of 2005 funds to be used
for purchase of drugs, and therefore, the country immedi-
ately places an $800,000 ACT order to cover yearly drug
requirements. ACT arrives in staggered shipments
throughout the year, until all $800,000 worth have been
delivered by the end of 2005. Once the amount of funding
for drugs had been predicted for each grant, amounts were
summed across all grants for a particular country to deter-
mine predicted funding available for ACT procurement in
that country, and globally, to examine the amount of ACT
procurement the Global Fund may fund each year.
To validate predictions of country-specific ACT demand
generated using this approach, data were collected on ACT
importation supported by specific Global Fund grants.
Validation requires a complete set of importation records
for all the ACT procured using Global Fund grants, includ-
ing the date of all deliveries, total volumes, and their
prices. Although partial records were obtained from sev-
eral countries, comprehensive importation records were
compiled for only two grants: one awarded during the first
funding round to a Southern African country and one
awarded in Round 4 to a country in East Africa. Data on
all ACT orders placed and shipments received were
obtained from sources including the National Medical
Stores, the National Drug Authorities, and the Ministries
of Health or Malaria Control Programmes. Cumulative
dollars spent on ACT over time were summed from these
records and compared to forecasted procurement.
Results
Through Round 7, 143 malaria grants had been awarded
to 158 principal recipients (15 grants had two recipient
organizations) in 75 countries or multi-country coopera-
tives. Fitting regression lines to each grant's cumulative
disbursement resulted in smoothed quarterly estimates of
total disbursements from the Global Fund to recipient
countries (Figure 3). Smoothed quarterly estimates were
correlated with actual disbursements, with r = 0.565 (p <
0.01). Three-quarters of Round 1–6 grants (no grants in
Round 7 had begun disbursement at the time of analysis)
with at least three disbursements (n = 97) were used in a
repeated split-sample procedure to select best-predicting
variables and fit final predictive regression models fore-
casting disbursement slopes and intercepts [see Addi-
tional Files – Additional File 1]. In these models, the
disbursement slope was positively associated with the
total agreed funding, the maximum potential size of
phase one of the grant, being located in East Africa, the
funding round in which the grant was awarded, and the
World Bank's rating of that country's control of corrup-
tion. Slope was negatively associated with agreed funding
for phase two of the grant.
In the final model predicting the intercept, or date on
which funding was predicted to begin disbursement, ear-
lier initiation of disbursement was associated with being
located in the African or American WHO world regions,
having a grant in a later funding round, being ranked by
the World Bank with a better Government Effectiveness
Index, and having a lower Observer Human Rights Index
(fewer infractions). Disbursement began later for grants in
the Southeast Asian WHO region, grants requested for
longer periods of time (78% of Round 1–6 grants
requested five years of funding, while the rest requested
2–4 years of support), and for countries with greater num-
bers of malaria grants.
Using these models, disbursement slopes and intercepts
were predicted for the 33 grants in the validation set.
These predictions were compared against the smoothed
actual disbursement lines and the disbursements planned
in the grant application (Figure 4). Predicted yearly global
estimates averaged an error of +/- $3.05 M (6.7%) and
were significantly correlated with the fit lines (r = 0.998, p
< 0.0001). Yearly error ranged from $1.0 M (1.1%) in
2005 to $4.9 M (20.6%) in 2003. Quarterly percent error
was higher than yearly error, with an average of +/-
$875,503 (11.7%) per quarter, but quarterly estimates
Smoothed quarterly disbursements versus actual quarterly  disbursements Figure 3
Smoothed quarterly disbursements versus actual 
quarterly disbursements. Comparison of smoothed quar-
terly approximations from regressing cumulative disburse-
ments against time and actual quarterly disbursements on all 
Global Fund malaria grants from funding Round 1–6.
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were still highly and significantly correlated with fit lines
(r = 0.987, p < 0.0001). Quarterly estimates from the sim-
ple summation of planned funding were also significantly
correlated with smoothed quarterly disbursements (r =
0.919, p < 0.0001), but were less accurate than the predic-
tion model with an average error of +/- $7.0 M (43.5%)
per quarter and +/- $28.1 M per year (40.9%).
Predicted ACT procurement
The antimalarial procurement plans outlined in grant pro-
posals were used to estimate the fraction of disbursements
funding ACT procurement for each grant. Multiplying
these fractions by the predicted yearly disbursement
amounts for each funding round produced the round-spe-
cific global funding estimates depicted in Table 2.
To examine whether the model could successfully predict
actual procurement supported by individual Global Fund
grants, ACT procurement predictions were validated
against procurement records from two sub-Saharan coun-
tries, one supported by a Round 4 grant and the other by
a Round 1 grant. Actual procurement records indicated
that the Round 4 grant (Figure 3A) supported the impor-
tation of 20.7 M artemether-lumefantrine treatments,
with a value of US $30.1 M, as of 27 June 2007, while the
Round 1 grant (Figure 3B) supported the procurement of
8.4 M treatments as of 8 May 2007 at a cost of $11.2 M.
The model's ACT procurement predictions succeeded in
approximating actual purchases. For the Round 4 grant,
daily cumulative ACT cost predictions were significantly
correlated with actual cumulative daily expenditure, with
r = 0.938 (p < 0.0001). The model predicted the grant
would support yearly delivery of $19.99 M worth of ACTs;
in reality, $23.41 M of treatments were delivered in 2006
(error = $3.42 M), while deliveries in 2007 were on pace
to reach $13.87 M. Likewise, daily cumulative ACT cost
predictions were very significantly correlated with actual
cumulative daily expenditure for ACT using the Round 1
grant (r = 0.945, p < 0.0001). The model predicted yearly
delivery of $2.40 M in ACT; in reality, $4.03 M worth of
treatments was delivered in 2004 (error = $1.6 M), $2.47
M in 2005 (error = $0.07 M), and $2.61 M in 2006 (error
= $0.21 M).
Discussion
An accurate forecast of global demand is dependent upon
a thorough understanding of the availability of resources
to support antimalarial procurement, in particular from
the Global Fund, at present the single largest funding
source. This analysis derived predictive regression models
that successfully forecasted the rate and timing of malaria
grant disbursement from the Global Fund to recipient
countries. Additionally, it was demonstrated that
smoothed disbursement rates provided accurate predic-
tion of ACT procurement funded by specific malaria Glo-
bal Fund grants in two countries. More data from other
countries in different regions and epidemiological and
political contexts will be necessary to further validate this
approach.
Predicted quarterly disbursements Figure 4
Predicted quarterly disbursements. Comparison of 
quarterly disbursements on 33 Global Fund malaria grants in 
the validation dataset as (1) calculated from the actual 
smoothed slopes, (2) estimated from predictive models, and 
(3) summed from disbursement planned in grant proposals.
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Table 2: Predicted Global Fund disbursements for ACTs (in $US)
Round 2003 2004 2005 2006 2007 2008
1 174,062 3,292,628 3,394,641 3,411,586 3,104,795 3,025,509
2 - 5,511,019 11,737,573 11,574,975 9,066,550 7,012,194
3 - 38,876 2,614,055 3,007,743 2,959,491 2,384,943
4 - - 4,231,787 64,863,377 65,816,864 66,073,528
5 - - - 1,866,298 16,332,993 16,657,853
6 - - - - 1,657,285 11,358,460
7 - - - - - 2,666,991
Total 174,062 7,486,696 18,054,214 64,461,682 76,303,706 85,902,497Malaria Journal 2008, 7:200 http://www.malariajournal.com/content/7/1/200
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This investigation constructed models to predict the rate
at which grants were disbursed from the Global Fund to
recipient countries, rather than the exact days and magni-
tudes of discrete disbursements. By predicting disburse-
ment rate, rather than discrete disbursements, it is
acknowledged that precise prediction of actual quarterly
disbursements – with their stochastic temporal patterning
(Figure 3) – is impractical. Predicting discrete disburse-
ments may be the ultimate goal of forecasting efforts for
the purpose of intervention planning at a country level,
since knowing when resources will be available is crucial
to planning efforts. However, the smoothed rates fore-
casted here, which distribute error across time rather than
attempting to estimate specific days on which disburse-
ments occur, appear to be sufficient for general prediction
of ACT procurement. In the two countries for which vali-
dation data were collected (Figure 5), this approach
appears useful for forecasting the significant portion of
global ACT demand driven by Global Fund grants. The
rate of grant disbursement is closely tied to the rate of ACT
procurement because Global Fund grants are perform-
ance-based, meaning that the disbursement slope is an
indicator of grant progress. As such, if a substantial por-
tion of a particular grant is intended for ACT procurement,
a large disbursement slope may be considered indicative
of successful procurement, and the magnitude and timing
of that procurement can be estimated as a function of the
disbursement slope.
One potential problem with using the disbursement rate
as a proxy for the ACT procurement rate is that the Global
Fund considers the entirety of a grant when determining
performance, so an underperforming component (e.g.,
insecticide-treated nets) may delay disbursement of a
grant even if ACT procurement is in fact on schedule.
However, the subsequent funding delays also will affect
all activities funded by the grant, including ACT procure-
ment, so a slower rate of disbursement will remain associ-
ated with the procurement rate even though the causality
of the association is reversed. Additionally, modeling each
grant individually and aggregating for a global total allows
a "portfolio" approach to forecasting, in which random
error in estimation of funds in one country is balanced by
the random error in another.
Some, although not all, of the factors identified here, like
measures of government effectiveness and grant size, were
similar to those identified in prior investigations [12,13].
Certain variables, such as national health spending, were
found to be associated with disbursement in prior analy-
ses but did not improve predictive models here, indicating
that a variable may be associated with grant performance
without being useful for prediction [16]. Unsurprisingly,
factors found to be predictive of the rate at which funding
was disbursed included several variables related to the size
of the grant, including being located in East Africa
(through Rounds 1–6, the average total potential size of
malaria grants awarded to East African countries was US
$44 million, compared to an average of $17 million for
malaria grants to the rest of the world). However, even
after controlling for these factors describing the grant size,
additional variables related to other grant and country
characteristics remained in the models as important pre-
dictive factors. Grants awarded in a later round were
found on average to have larger grant disbursement rates,
while countries ranked as having more corruption dis-
played smaller rates. Amongst other factors, the intercept
of the disbursement line (timing of the initial disburse-
ment) was predicted by the World Bank rating for govern-
ment effectiveness, with more effective governments
averaging an earlier start date, and the Observer compila-
tion of human rights violations, with countries scoring
worse averaging later start dates. These results appear to
indicate that effective, efficient governments with respect
for human rights were better able to navigate the grant
signing process and to receive initial disbursements more
rapidly than less effective governments.
This methodology provides a means of forecasting ACT
procurement driven by Global Fund grants over their
lifespan which appears to be more accurate than reliance
upon planned funding, although the magnitude of the
increase in predictive accuracy varies by year (Figure 4).
Past experiences in ACT implementation in Sudan [20]
and Kenya [21], among others, have demonstrated the
unforeseen obstacles that may affect grant progress and
Prediction of ACT procurement in two countries Figure 5
Prediction of ACT procurement in two countries. 
Validation of predicted disbursements and ACT procure-
ment for (a) a Round 4 grant to a country in East Africa and 
(b) a Round 1 grant to a country in Southern Africa with 
actual disbursement and ACT importation records.
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underscore the need for approaches that incorporate such
delays when forecasting resources for ACT procurement.
Simple summation of planned procurement overesti-
mated true procurement by 63% in 2005, 51% in 2006,
and 17% in 2007. Recent market instability, including
dramatic changes in the price of artemisinin, have been
linked to overestimates of demand in past forecasts
[4,22], emphasizing the need to account for the fact that
actual disbursement and utilization of Global Fund grants
tend to occur behind schedule [23].
Ultimately, a global forecast useful for planning drug pro-
duction and artemisinin cultivation must predict demand
for ACT on a product- and dosage-specific basis. The Glo-
bal Fund-driven ACT funding predicted by this model
provides a foundation for such a robust, accurate demand
forecast. Conversion of ACT funding into product- and
dosage-specific treatments, and subsequently into active
pharmaceutical ingredients and artemisinin require-
ments, may be performed using information contained in
Global Fund proposals specifying exact products to be
procured, country malaria guidelines dictating public sec-
tor product choice, and epidemiological and demo-
graphic characteristics which, in the absence of other
information on planned procurement, can be used to esti-
mate the relative age-specific breakdown of dosages
required. These calculations must include consideration
for how the price of ACT may have decreased since the
country planned its ACT procurement in its Global Fund
proposal, thus altering the volume of drugs that can be
purchased with the predicted disbursements.
An accurate forecast of future Global Fund supported ACT
procurement is an important component of robust global
demand estimation. However, estimating total global
demand for antimalarials must also consider the role
played by other important public sector funding organiza-
tions, including the World Bank, the United States Presi-
dent's Malaria Initiative, and UNITAID, as well as the
growing importance of private sector procurement. Addi-
tionally, the methods described here cannot predict pro-
curement funded by grants not yet awarded by the Global
Fund. These components of the global demand require
separate forecasts.
Conclusion
This report describes an approach to predicting the size
and timing of the Global Fund monetary disbursements
that will continue to be used to drive the bulk of ACT pur-
chases, at least until implementation of a global subsidy
for ACT, currently being discussed by the international
malaria community, becomes a reality. The evidence sug-
gests that this approach is more accurate than forecasting
based on planned funding from the grant proposals.
Approaches like this one are useful tools for building
comprehensive, robust models of global ACT demand
that can help ensure affordable, universal access to these
life-saving drugs.
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